All In MedTech

Device Trial Radar · NCT02749110

Participation in Screening for Cervical Cancer: Interest of a Self-sampling Device Provided by the General Practitioner

Participation in Screening for Cervical Cancer: Interest of a Human Papillomavirus (HPV) Self-sampling Device Provided by the General Practitioner; a Cluster Randomized Clinical Trial

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 308 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

308

Actual

Start

Aug 28, 2016

Primary completion

Aug 23, 2019

Study completion Feb 23, 2021

Sponsor

Lead sponsor
University Hospital, LilleAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Health, France
First posted
Apr 22, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
Who can join
Female only, from 30 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study evaluates the benefit in women aged from 30 to 65 years, who do not participate to the French opportunistic cervical cancer screening program, of an organized screening with the proposition by the family physician of a pap-test (usual care) versus a self-collected vaginal sample (and a HPV-test). 24 family physicians will participate and will be randomized in the usual care arm (12) or in the self-sampling arm (12). Our hypothesis is that organizing the screening for these women involving their family physician will major participation, and that the self-sampling option will amplify this increase.

Conditions

  • Malignant Tumor of Cervix
  • Cervical Intraepithelial Neoplasia

Interventions

  • Vaginal self-sampling brushDevice

    Self-collection by unscreened women aged from 30 to 65 of a vaginal sample with the device. After collection, the whole device is mailed in a normalized for biological samples package to the virology lab of the University Hospital of Lille where a HPV test is conducted using a Cobas 4800 technique.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of women terminating the whole diagnostic process.Time frame: For screening: 12 months; for follow-up of screened positive subjets: 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Doctor's office 115

    Herzeele, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.